AstraZeneca Acquires Modella AI to Speed Up Oncology Drug Research

AstraZeneca has acquired Boston-based Modella AI to accelerate oncology drug research. The deal integrates Modella's foundation models and AI agents into AstraZeneca's global oncology R&D pipeline. Announced on January 13 at JPMorgan Healthcare Conference, this marks the first acquisition of an AI firm by a major pharmaceutical company.

Oncology generates large amounts of multimodal data daily, histopathology slides, genomic sequencing, and clinical records. Traditional analysis relies on manual pathologist review. Modella AI trains foundation models across these data types simultaneously, then deploys AI agents that refine predictions with streaming patient data.

The acquisition targets "quantitative pathology," AI analysis of biopsies for protein expression and clinical correlation. "Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer. Computers now quantify expression across thousands of cells per slide and nominate therapeutic targets at machine speed.​

In an interview at the J.P. Morgan Healthcare Conference, AstraZeneca ‍ Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.